cas 1643462-61-6|| where to buy tert-butyl4-bromo-3,5-dimethyl-2,6-dioxo-3,6-dihydropyrimidine-1(2H)-carboxylate

Nombre del producto:tert-butyl4-bromo-3,5-dimethyl-2,6-dioxo-3,6-dihydropyrimidine-1(2H)-carboxylate

IUPAC Name:tert-butyl 4-bromo-3,5-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-1-carboxylate

Unidad de embalaje	Stock disponible	Precio($)	Cantidad

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1643462-61-6 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :1643462-61-6; Fórmula molecular:C11H15BrN2O4; Punto de fusión:-; Código de sonrisas:O=C(N(C(N(C)C(Br)=C1C)=O)C1=O)OC(C)(C)C; Densidad:

: Número de catálogo:CM336709; Peso molecular:319.16; Punto de ebullición:; Nº Mdl:; Almacenamiento:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Tavapadon; Cerevel Therapeutics announces positive topline results for Tavapadon in phase 3 adjunctive trial for people living with Parkinson’s disease. The TEMPO-3 trial evaluated its efficacy, safety and tolerability met the primary endpoint and key secondary endpoint. The neurotransmitter dopamine is linked to working memory and motor movement, and the loss of dopamine-producing neurons in the brain result in Parkinson’s disease.
Tavapadon is a selective dopamine D1/D5 receptor partial agonist for the improved motor control. While most dopamine agonists target and stimulate D2/D3 dopamine receptors, Tavapadon is the only D1/D5 selective partial agonist in clinical development for PD.